Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 9/20 | 1.00 |
| ▸ | ITPR1 | Q14643 | 5/20 | 1.00 |
| ▸ | ITPR2 | Q14571 | 4/20 | 1.00 |
| ▸ | INPP5A | Q14642 | 2/20 | 1.00 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.90 |
| ▸ | AKT1 | P31749 | 1/20 | 0.90 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ins(1,4,5)P3 SCHEMBL9383914 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL4871682 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL28087353 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL9382320 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL98182 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL10490812 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL4321735 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL381458 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| Ins(1,4,5)P3 SCHEMBL4874594 | 1.00 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 | |
| SCHEMBL19532798 | 0.94 | ITPR3 (1.00) | ITPR3ITPR1ITPR2INPP5AINPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408481-A2 | MAGNETIC RESONANCE IMAGING CONTRAST AGENT WITH PARAMAGNETIC-INOSITOL PHOSPHATES COMPLEXES | Gachon University Of Medicine&Science Industry- Academic Cooperation Foundation (KR) | 2012-01-25 | — | — | EP | claimed |
| WO-2010107178-A2 | MAGNETIC RESONANCE IMAGING CONTRAST AGENT WITH PARAMAGNETIC-INOSITOL PHOSPHATES COMPLEXES | GACHON UNIVERSITY OF MEDICINE & SCIENCE INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2010-09-23 | — | — | WO | claimed |
| US-20100233093-A1 | Magnetic resonance imaging contrast agent with paramagnetic-inositol phosphates complexes | GACHON UNIVERSITY OF MEDICINE & SCIENCE INDUSTRY-ACADEMIC CORPERATION FOUNDATION (KR) | 2010-09-16 | — | — | US | claimed |
| EP-0954320-A4 | INOSITOL POLYPHOSPHATE DERIVATIVES AND METHODS OF USING SAME | UNIV CALIFORNIA (US) | 2001-04-04 | — | — | EP | claimed |
| EP-0954320-A1 | INOSITOL POLYPHOSPHATE DERIVATIVES AND METHODS OF USING SAME | The Regents of the University of California (US) | 1999-11-10 | — | — | EP | claimed |
| US-5977078-A | CELL PERMEABLE ANTAGONIST | THE REGENTS OF THE UNIVESITY OF CALIFORNIA (US) | 1999-11-02 | — | — | US | claimed |
| WO-1998011901-A1 | INOSITOL POLYPHOSPHATE DERIVATIVES AND METHODS OF USING SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-03-26 | — | — | WO | claimed |
| US-5330979-A | Administering to treat nervous system and cardiovascular disorders | PERSTORP AB (SE) | 1994-07-19 | — | — | US | claimed |
| US-5128332-A | Method of treating cardiovascular diseases using inositoltrisphosphate | PERSTORP AB (SE) | 1992-07-07 | — | — | US | claimed |
| US-5057507-A | Method of alleviating bone damage with inositoltriphosphate | PERSTORP AB (SE) | 1991-10-15 | — | — | US | claimed |
| EP-3704262-B1 | MULTIPLEXED ANALYSIS OF MATERIALS FOR TISSUE DELIVERY | GEORGIA TECH RES INST (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2020247382-A1 | ANALYSIS OF MATERIALS FOR TISSUE DELIVERY | GUIDE THERAPEUTICS, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200330607-A1 | Multiplexed Analysis of Materials for Tissue Delivery | GEORGIA TECH RESEARCH CORPORATION | 2020-10-22 | — | — | US | disclosed |
| US-10039715-B2 | Liposomal formulation of nonglycosidic ceramides and uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2654779-B1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INST FOR CANCER RES LTD (US) | 2018-02-28 | — | — | EP | disclosed |
| US-4851560-A | Inositol triphosphates | PERSTORP AB (SE) | 1989-07-25 | — | — | US | disclosed |
| US-4793945-A | STABILIZING ORGANIC SUBSTRATE SUBJECT TO DEGRADATION BY OXIDATION AND-OR FREE RADICAL REACTION | PERSTORP AB (SE) | 1988-12-27 | — | — | US | disclosed |
| US-4794014-A | COUNTERACTING DELITERIOUS EFFECTS OF HEAVY METALS, RADIATION AND SMOKING | PERSTORP AB (SE) | 1988-12-27 | — | — | US | disclosed |
| WO-1988007047-A1 | INOSITOL PHOSPHATE ANALOGUES | RESEARCH CORPORATION LIMITED (GB) | 1988-09-22 | — | — | WO | disclosed |
| US-4755612-A | Intermediate compounds resulting from method for forming a dihydrogen-phosphate inositol | MERCK & CO., INC. (US) | 1988-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10039715-B2 | Liposomal formulation of nonglycosidic ceramides and uses thereof | CERS2, CERT1, SGMS1 | ITPR3 238/4885ITPR1 331/4885ITPR2 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.